The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma

被引:31
作者
Jones, D
Fletcher, CDM
Pulford, K
Shahsafaei, A
Dorfman, DM
机构
[1] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Hematopathol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
[4] Univ Oxford, John Radcliffe Hosp, Dept Cellular Sci, Immunodiagnost Unit,Leukemia Res Fund, Oxford OX3 9DU, England
关键词
D O I
10.1182/blood.V93.10.3487.410k39_3487_3493
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The tumor necrosis factor (TNF) receptor family includes several important markers of activation in T cells. We examined expression patterns of two T-cell-associated members of these receptors, namely CD30 and OX40/CD134, in 148 cases of T-cell lymphoma to identify possible objective immunohistochemical criteria for subclassification of these tumors. CD30 expression was characteristic of tumors with an anaplastic (46/47 cases [98%]) or large-cell (10/21 [48%]) morphology and was seen in only scattered cells in other tumor types, In contrast, large numbers of OX40/CD134(+) tumors cells were typical of angioimmunoblastic lymphoma (15/16 [94%]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a prominent histiocytic component (6/7 [86%]). Strong OX40/ CD134 and CD30 coexpression was seen in only 4% of tumors, typically those with an anaplastic/Hodgkin's-like appearance. OX40/CD134 expression was characteristic of tumors composed of activated CD4(+) T cells and was not seen in small-cell T-cell lymphomas, lymphoblastic lymphomas, or other tumor types, including B-cell lymphomas or carcinomas. These results suggest that immunostaining for OX40/CD134 may be helpful in subclassification of peripheral T-cell lymphomas and that the patterns of TNF receptor family expression in these tumors may parallel those seen within nonneoplastic helper T-cell subsets. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:3487 / 3493
页数:7
相关论文
共 55 条
[11]  
Dorfman DM, 1996, MODERN PATHOL, V9, P959
[12]   EXPRESSION OF THE HUMAN OX40 (HOX40) ANTIGEN IN NORMAL AND NEOPLASTIC TISSUES [J].
DURKOP, H ;
LATZA, U ;
HIMMELREICH, P ;
STEIN, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (04) :927-931
[13]   CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1 [J].
Flynn, S ;
Toellner, KM ;
Raykundalia, C ;
Goodall, M ;
Lane, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (02) :297-304
[14]   Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules [J].
Foss, HD ;
Anagnostopoulos, I ;
Araujo, I ;
Assaf, C ;
Demel, G ;
Kummer, JA ;
Hummel, M ;
Stein, H .
BLOOD, 1996, 88 (10) :4005-4011
[15]   CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin [J].
Gattei, V ;
Degan, M ;
Gloghini, A ;
DeIuliis, A ;
Improta, S ;
Rossi, FM ;
Aldinucci, D ;
Perin, V ;
Serraino, D ;
Babare, R ;
Zagonel, V ;
Gruss, HJ ;
Carbone, A ;
Pinto, A .
BLOOD, 1997, 89 (06) :2048-2059
[16]  
Gilfillan MC, 1998, J IMMUNOL, V160, P2180
[17]   IDENTIFICATION OF A HUMAN OX-40 LIGAND, A COSTIMULATOR OF CD4+ T-CELLS WITH HOMOLOGY TO TUMOR-NECROSIS-FACTOR [J].
GODFREY, WR ;
FAGNONI, FF ;
HARARA, MA ;
BUCK, D ;
ENGLEMAN, EG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (02) :757-762
[18]   CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues [J].
Gruss, HJ ;
Herrmann, F ;
Gatei, V ;
Gloghini, A ;
Pinto, A ;
Carbone, A .
LEUKEMIA & LYMPHOMA, 1997, 24 (5-6) :393-+
[19]  
Hamann D, 1996, J IMMUNOL, V156, P1387
[20]  
HARRIS NL, 1994, BLOOD, V84, P1361